Precautions for drug infusion for bladder cancer

Bladder cancer is the most common tumor in the urinary system. Surgical treatment should be taken promptly after diagnosis. The recurrence rate of bladder cancer is high within 2 years after surgery. Intravesical chemotherapy is currently the most commonly used measure to prevent tumor recurrence after bladder cancer surgery. The purpose is to exert the cytotoxic effect of anticancer drugs, kill residual tumor cells, tiny lesions or carcinoma in situ in the bladder, and reduce the recurrence of bladder tumors. It can be said that this method is simple and convenient to operate.

There are currently two types of chemotherapy drugs for bladder: biological agents, such as BCG, and chemical drugs, such as mitomycin and pirarubicin. The ideal bladder instillation drug is one that can quickly reach an effective drug concentration in the bladder epithelium, with less systemic absorption and fewer adverse reactions.
Although perfusion therapy concentrates the drugs in one place, the side effects on normal cells in other parts of the body are less, but they are still inevitable. For example, drug perfusion for bladder cancer often causes complications such as prostatitis, cystitis, and bladder bleeding in men. The use of chemotherapy drugs will inevitably cause damage to normal cells. During perfusion therapy, it is necessary to use the traditional Chinese medicine ginsenoside Rh2 to regulate and relieve the toxic side effects of chemotherapy. When the monomer content of ginsenoside Rh2 is higher than a certain level, it can produce a synergistic anti-cancer effect with chemotherapy drugs to reduce the amount of drugs used and reduce the harm of chemotherapy to the body.